Evaluation of the safety, pharmacokinetics, and antitumor activity of tusamitamab ravtansine in patients with nonsquamous non-small cell lung cancer with high or moderate expression of carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) | Publicación